Arv­inas ends plans for two Phase 3 breast can­cer tri­als; Phath­om makes cuts

Plus, news about Re­pare Ther­a­peu­tics, DCx Bio­ther­a­peu­tics, Blooms­bury Ge­net­ic Ther­a­pies and Zu­cara Ther­a­peu­tics:

Arv­inas drops planned late-stage tri­als: The pro­tein de­grad­er spe­cial­ist, along with its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER